Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 29097609.
- Also identified by DOI 10.1158/0008-5472.CAN-17-2066 and PMC identifier 5712276.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This review describes the pivotal roles of cell-cycle and checkpoint regulators and discusses development of specific cell-cycle inhibitors for therapeutic use for pediatric cancer. The mechanism of action as well as the safety and tolerability of drugs in pediatric patients, including compounds that target CDK4/CDK6 (palbociclib, ribociclib, and abemaciclib), aurora kinases (AT9283 and MLN8237), Wee1 kinase (MK-1775), KSP (ispinesib), and tubulin (taxanes, vinca alkaloids), are presented. The design of mechanism-based combinations that exploit the cross-talk of signals activated by cell-cycle arrest, as well as pediatric-focused drug development, are critical for the advancement of drugs for rare childhood diseases. <i>Cancer Res; 77(23); 6489-98. ©2017 AACR</i>.
Medical subject headings
- Cell Cycle
- Cell Cycle Checkpoints
- Cyclin-Dependent Kinase 4
- Cyclin-Dependent Kinase 6
- Neoplasms
- Protein Kinase Inhibitors